publication . Article . 2011

Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials

Andrew S Holpuch; Kashappa-Goud H Desai; Steven P Schwendeman; Susan R Mallery;
Open Access English
  • Published: 01 Sep 2011 Journal: Journal of Carcinogenesis, volume 10 (issn: 0974-6773, eissn: 1477-3163, Copyright policy)
  • Publisher: Medknow Publications
Abstract
Due to its characterized progression from recognized premalignant oral epithelial changes (i.e., oral epithelial dysplasia) to invasive cancer, oral squamous cell carcinoma represents an optimal disease for chemopreventive intervention prior to malignant transformation. The primary goal of oral cancer chemoprevention is to reverse, suppress, or inhibit the progression of premalignant lesions to cancer. Over the last several decades, numerous oral cancer chemoprevention clinical trials have assessed the therapeutic efficacy of diverse chemopreventive agents. The standard of care for more advanced oral dysplastic lesions entails surgical excision and close clinica...
Subjects
mesheuropmc: stomatognathic diseases
free text keywords: Review Article, Chemoprevention, RC254-282, pharmacologic advantage, local drug delivery, oral cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Funded by
NIH| Chemoprevention of Head & Neck Cancer Using Controlled Release Polymers
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01CA129609-05
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Chemopreventive Effects of Black Raspberries and Fenretinide in Oral Mucosa
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5F30DE020992-04
  • Funding stream: NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH
,
NIH| Comprehensive Training in Oral and Craniofacial Sciences
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5T32DE014320-17
  • Funding stream: NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH
,
NIH| Protein Stability in Polymer Delivery Systems
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01HL068345-08
  • Funding stream: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
,
NIH| Clinical evaluation of a bioadhesive gel for oral cancer chemoprevention.
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1RC2CA148099-01
  • Funding stream: NATIONAL CANCER INSTITUTE
78 references, page 1 of 6

Deeken, JF, Slack, R, Marshall, JL. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer. 2008; 113: 1502-10 [PubMed]

Gonzalez-Angulo, AM, Morales-Vasquez, F, Hortobagyi, GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608: 1-22 [PubMed]

Baban, DF, Seymour, LW. Control of tumour vascular permeability. Adv Drug Deliv Rev. 1998; 34: 109-19 [PubMed]

Maeda, H, Sawa, T, Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001; 74: 47-61 [PubMed]

Pegram, MD, Lipton, A, Hayes, DF, Weber, BL, Baselga, JM, Tripathy, D. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998; 16: 2659-71 [PubMed]

Denny, WA. The role of hypoxia-activated prodrugs in cancer therapy. Lancet Oncol. 2000; 1: 25-9 [PubMed]

Abdollahi, A, Folkman, J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010; 13: 16-28 [PubMed]

Murray, N, Turrisi, AT. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol. 2006; 1: 270-8 [PubMed]

Scagliotti, G, Govindan, R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist. 2010; 15: 436-46 [OpenAIRE] [PubMed]

Shen, YC, Hsu, C, Cheng, AL. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol. 2010; 45: 794-807 [PubMed]

Shen, Z, Shen, T, Wientjes, MG, O’Donnell, MA, Au, JL. Intravesical treatments of bladder cancer: review. Pharm Res. 2008; 25: 1500-10 [OpenAIRE] [PubMed]

Sood, S, Shiff, SJ, Yang, CS, Chen, X. Selection of topically applied non-steroidal anti-inflammatory drugs for oral cancer chemoprevention. Oral Oncol. 2005; 41: 562-7 [PubMed]

Mallery, SR, Stoner, GD, Larsen, PE, Fields, HW, Rodrigo, KA, Schwartz, SJ. Formulation and in-vitro and in-vivo evaluation of a mucoadhesive gel containing freeze-dried black raspberries: implications for oral cancer chemoprevention. Pharm Res. 2007; 24: 728-37 [OpenAIRE] [PubMed]

Sporn, MB, Dunlop, NM, Newton, DL, Smith, JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976; 35: 1322-28 [PubMed]

Senel, S, Ikinci, G, Kaş, S, Yousefi-Rad, A, Sargon, MF, Hincal, AA. Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery. Int J Pharm. 2000; 193: 197-203 [PubMed]

78 references, page 1 of 6
Abstract
Due to its characterized progression from recognized premalignant oral epithelial changes (i.e., oral epithelial dysplasia) to invasive cancer, oral squamous cell carcinoma represents an optimal disease for chemopreventive intervention prior to malignant transformation. The primary goal of oral cancer chemoprevention is to reverse, suppress, or inhibit the progression of premalignant lesions to cancer. Over the last several decades, numerous oral cancer chemoprevention clinical trials have assessed the therapeutic efficacy of diverse chemopreventive agents. The standard of care for more advanced oral dysplastic lesions entails surgical excision and close clinica...
Subjects
mesheuropmc: stomatognathic diseases
free text keywords: Review Article, Chemoprevention, RC254-282, pharmacologic advantage, local drug delivery, oral cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Funded by
NIH| Chemoprevention of Head & Neck Cancer Using Controlled Release Polymers
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01CA129609-05
  • Funding stream: NATIONAL CANCER INSTITUTE
,
NIH| Chemopreventive Effects of Black Raspberries and Fenretinide in Oral Mucosa
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5F30DE020992-04
  • Funding stream: NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH
,
NIH| Comprehensive Training in Oral and Craniofacial Sciences
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5T32DE014320-17
  • Funding stream: NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH
,
NIH| Protein Stability in Polymer Delivery Systems
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01HL068345-08
  • Funding stream: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
,
NIH| Clinical evaluation of a bioadhesive gel for oral cancer chemoprevention.
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1RC2CA148099-01
  • Funding stream: NATIONAL CANCER INSTITUTE
78 references, page 1 of 6

Deeken, JF, Slack, R, Marshall, JL. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer. 2008; 113: 1502-10 [PubMed]

Gonzalez-Angulo, AM, Morales-Vasquez, F, Hortobagyi, GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608: 1-22 [PubMed]

Baban, DF, Seymour, LW. Control of tumour vascular permeability. Adv Drug Deliv Rev. 1998; 34: 109-19 [PubMed]

Maeda, H, Sawa, T, Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001; 74: 47-61 [PubMed]

Pegram, MD, Lipton, A, Hayes, DF, Weber, BL, Baselga, JM, Tripathy, D. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998; 16: 2659-71 [PubMed]

Denny, WA. The role of hypoxia-activated prodrugs in cancer therapy. Lancet Oncol. 2000; 1: 25-9 [PubMed]

Abdollahi, A, Folkman, J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010; 13: 16-28 [PubMed]

Murray, N, Turrisi, AT. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol. 2006; 1: 270-8 [PubMed]

Scagliotti, G, Govindan, R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist. 2010; 15: 436-46 [OpenAIRE] [PubMed]

Shen, YC, Hsu, C, Cheng, AL. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol. 2010; 45: 794-807 [PubMed]

Shen, Z, Shen, T, Wientjes, MG, O’Donnell, MA, Au, JL. Intravesical treatments of bladder cancer: review. Pharm Res. 2008; 25: 1500-10 [OpenAIRE] [PubMed]

Sood, S, Shiff, SJ, Yang, CS, Chen, X. Selection of topically applied non-steroidal anti-inflammatory drugs for oral cancer chemoprevention. Oral Oncol. 2005; 41: 562-7 [PubMed]

Mallery, SR, Stoner, GD, Larsen, PE, Fields, HW, Rodrigo, KA, Schwartz, SJ. Formulation and in-vitro and in-vivo evaluation of a mucoadhesive gel containing freeze-dried black raspberries: implications for oral cancer chemoprevention. Pharm Res. 2007; 24: 728-37 [OpenAIRE] [PubMed]

Sporn, MB, Dunlop, NM, Newton, DL, Smith, JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976; 35: 1322-28 [PubMed]

Senel, S, Ikinci, G, Kaş, S, Yousefi-Rad, A, Sargon, MF, Hincal, AA. Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery. Int J Pharm. 2000; 193: 197-203 [PubMed]

78 references, page 1 of 6
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2011

Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials

Andrew S Holpuch; Kashappa-Goud H Desai; Steven P Schwendeman; Susan R Mallery;